聯影醫療擬斥4億元-8億元回購公司股份,進一步增強投資者信心
8月22日,聯影醫療發佈《關於以集中競價交易方式回購公司股份方案的公吿》,基於對公司未來發展的信心和對公司價值的認可,為建立完善公司長效激勵機制,促進公司穩定、健康、可持續發展,公司擬通過集中競價交易方式進行股份回購。本次回購的資金總額不低於人民幣4億元(含),不超過人民幣8億元(含),擬回購的價格為不超過人民幣140元/股(含)。回購是上市公司基於利好預期的自我反饋,聯影醫療在2023年上半年營收和淨利潤均實現超20%同比增長,且股東及董監高已自願延長所持股份鎖定期的情況下,再發回購公吿,彰顯公司信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.